Understanding resilience to Alzheimer's disease in Colombian families with genetic mutations
Official title: Resilience to Cognitive Decline and Resistance to Alzheimer's Disease and Related Neurodegenerative Diseases in Individuals from Colombia with Autosomal Dominant Dementias
Funded at Massachusetts General Hospital · NIH-10721433 · Data updated 2026-11-12
This study is looking at how specific genetic changes linked to early-onset Alzheimer's disease impact memory and thinking skills in people from Colombia, especially those with these mutations and their family members, to find out what helps some people stay mentally sharp despite the disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | August 15, 2023 |
| Project end | July 31, 2026 |
| Funding year | 2023 |
| Award (this year) | $3,821,618 |
| NIH project number | 1RM1NS132996-01 |
| Project ID | NIH-10721433 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation include individuals from Colombian families with known genetic mutations linked to early-onset Alzheimer's disease.
✕Less likely to help
Patients without genetic mutations associated with Alzheimer's disease or those not from the studied Colombian families may not benefit from this research.
What this research studies
This research investigates how certain genetic mutations associated with early-onset Alzheimer's disease affect cognitive decline in individuals from Colombia. By studying large families with these mutations, the research aims to identify biological factors that contribute to resilience against dementia. Participants will undergo genetic analysis and cognitive assessments to explore the relationship between genetic variants and neurodegenerative conditions. The study focuses on individuals who carry specific mutations, such as PSEN1, and their relatives, to better understand protective mechanisms against cognitive decline.
Why it matters
Potential benefit: If successful, this research could lead to new insights into preventing or delaying the onset of Alzheimer's disease and related dementias.
How similar studies have gone: Previous research has shown success in understanding genetic factors in Alzheimer's disease, making this approach promising and relevant.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: Quiroz, Yakeel T. — Massachusetts General Hospital
- Study coordinator: Quiroz, Yakeel T.
Related research
Other NIH-funded projects on the same topics.
-
Identifying early signs of Alzheimer's disease and resilience factors
This study is looking at new ways to spot early signs of Alzheimer's disease in older adults by examining brain activity, so we can help those at risk or who are doing well despite the challenges of aging.
-
How COVID-19 infection and genes may influence memory and dementia risk
This study looks at how getting COVID-19 and a person’s genes together affect the chance of developing memory problems and Alzheimer’s disease later in life.
-
NGF Metabolism as a biomarker for cognitive decline in familial Alzheimer's disease
Researchers are studying whether patterns in nerve growth factor pathways in blood and CSF can signal early, preclinical stages of Alzheimer's in people with genetic risk.
-
NGF metabolism as an early biomarker for cognitive decline in familial Alzheimer's disease
This project tests whether NGF pathway proteins in blood and CSF can signal early, preclinical changes in people with familial Alzheimer’s disease.
-
NGF Metabolic Dysfunction as a Marker of Cognitive Decline in Autosomal Dominant Alzheimer's Disease
This project looks at nerve growth factor pathways in people with a genetic form of Alzheimer's to see if blood and spinal fluid markers can identify early brain changes before symptoms appear.
-
Genetic and single-cell study of Alzheimer’s risk and resilience
Researchers will study how genes and cell-level signals contribute to Alzheimer’s risk and resilience, using human brains and mouse models to find clues for therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.